Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum

Autor: Ido P. Kema, Peter Paul De Deyn, Claude van der Ley, Jana Janssens, Martijn van Faassen, Yannick Vermeiren
Přispěvatelé: Lifestyle Medicine (LM), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Molecular Neuroscience and Ageing Research (MOLAR)
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Male
SYMPTOMS
L-DOPA
Biochemistry
METABOLITES
chemistry.chemical_compound
0302 clinical medicine
Cerebrospinal fluid
PARKINSONS-DISEASE
Monoaminergic
Medicine
Amyotrophic lateral sclerosis
Kynurenine
Neuropathology
Dopaminergic
General Medicine
EXPANSION
Middle Aged
Ventral tegmental area
Chemistry
medicine.anatomical_structure
QUINOLINIC ACID
Frontotemporal Dementia
Female
Frontotemporal dementia
medicine.medical_specialty
Neurophysiology
Substantia nigra
03 medical and health sciences
Cellular and Molecular Neuroscience
KYNURENINE PATHWAY
Internal medicine
mental disorders
Humans
Biogenic Monoamines
LOBAR DEGENERATION
Biology
Aged
Retrospective Studies
Original Paper
business.industry
Amyotrophic Lateral Sclerosis
Biomarker
medicine.disease
COGNITIVE IMPAIRMENT
nervous system diseases
030104 developmental biology
Endocrinology
chemistry
Dementia
Human medicine
ALS
business
030217 neurology & neurosurgery
Biomarkers
Quinolinic acid
Zdroj: Neurochemical Research, 45(5), 1191-1201
Neurochemical Research 45 (2020) 5
Neurochemical research
NEUROCHEMICAL RESEARCH, 45(5), 1191-1201. SPRINGER/PLENUM PUBLISHERS
Neurochemical Research
ISSN: 0364-3190
Popis: Exploring the neurochemical continuum between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) with respect to monoamines and kynurenines in cerebrospinal fluid (CSF) and serum, may be useful to identify possible new research/therapeutic targets. Hence, we analysed monoamines and kynurenines in CSF and serum derived from patients with FTD (n = 39), ALS (n = 23), FTD-ALS (n = 4) and age-matched control subjects (n = 26), using reversed-phase ultra-high performance liquid chromatography (RP-UHPLC) with electrochemical detection (ECD) and liquid chromatography tandem mass spectrometry, respectively. We noted a shared dopaminergic disturbance in FTD and ALS when compared to CONTR, with significantly increased serum DA levels and decreased DOPAC concentrations, as well as decreased DOPAC/DA ratios in both disease groups. In CSF, significantly reduced DOPAC concentrations in FTD and ALS were observed as well. Here, a significant increase in DA levels and decrease in DOPAC/DA ratios was only found in FTD relative to CONTR. With respect to the kynurenine pathway (KP), we only found decreased HK/XA ratios, indicative for vitamin B6 status, in serum of ALS subjects compared to FTD. The dopaminergic commonalities observed in FTD and ALS might relate to a disturbance of dopaminergic nerve terminals in projection areas of the substantia nigra and/or ventral tegmental area, although these findings should first be confirmed in brain tissue. Lastly, based on the results of this work, the KP does not hold promise as a research/therapeutic target in FTD and ALS. Electronic supplementary material The online version of this article (10.1007/s11064-020-03002-5) contains supplementary material, which is available to authorized users.
Databáze: OpenAIRE
Externí odkaz: